TACT trial: Chelation Therapy for the Treatment of Coronary Disease.

In theory, also as for certain diseases caused by mineral deposits, Chelation treatment with EDTA (Ethylene Diamine Tetra-Acetic Acid) could reduce calcium and cholesterol content, and oxidative stress of plates. The placebo-controlled double blind design study included 1708, randomized to EDTA + vitamins, EDTA + placebo, placebo + vitamins o placebo + placebo. Primary end point was a composite of death, infarction, revascularization and hospitalization for angina, with a 60 month follow up. The group EDTA vs. placebo showed less events (33% vs. 38% respectively p=0,03).

Conclusión: the administration of 40 EDTA sessions was safe and effective.

Comment: though it has a number of methodological limitations (such as a 20% follow up loss) and because the physiological mechanism of the EDTA effect remains unknown, this study should be considered as a hypothesis generator

Gervasio Lamas
2012-11-04

Original title: Results of the Trial to Assess Chelation Therapy (TACT Trial) 

*

Top